Merck says psoriasis, HDL, Alzheimer's drug trials moving ahead
Merck says psoriasis, HDL, Alzheimer's drug trials moving ahead Reuters
View ArticleCan Johnson & Johnson Cash In on Stelara?
Can Johnson & Johnson Cash In on Stelara? Motley Fool
View ArticleCelgene drug shown to be effective, safe in psoriasis trial
Celgene drug shown to be effective, safe in psoriasis trial Reuters
View ArticleDo These Pipeline Drugs Hold the Key to AbbVie's Future?
Do These Pipeline Drugs Hold the Key to AbbVie's Future? Motley Fool
View Article2 Sides of Celgene's Apremilast Results
2 Sides of Celgene's Apremilast Results Motley Fool
View ArticleCan New Psoriasis Drugs Scratch Investors' Itch?
Can New Psoriasis Drugs Scratch Investors' Itch? Investors.com
View ArticleCan Merck Field a Psoriasis Blockbuster?
Can Merck Field a Psoriasis Blockbuster? Motley Fool
View ArticleIs Celgene's Apremilast A Potential Blockbuster Or Not?
Is Celgene's Apremilast A Potential Blockbuster Or Not? Seeking Alpha
View ArticlePsoriasis Med Similiar To Biogen MS Pill Is Linked To Brain Disease
Psoriasis Med Similiar To Biogen MS Pill Is Linked To Brain Disease Pharmalot
View ArticleNovartis' psoriasis drug superior to Enbrel in study
Novartis' psoriasis drug superior to Enbrel in study Reuters
View ArticleXenoPort to continue development of XP23829 after Phase 1 results
XenoPort to continue development of XP23829 after Phase 1 results Yahoo/Fly on the Wall
View ArticleNew class of psoriasis drugs being developed
New class of psoriasis drugs being developed Bloomberg
View ArticlePsoriasis study does little to help Pfizer with Xeljanz
Psoriasis study does little to help Pfizer with Xeljanz Fierce Pharma
View ArticleIdera: A Compelling Biotech Pick For March
Idera: A Compelling Biotech Pick For March Seeking Alpha
View ArticleAbbVie's Humira Still a Growth Engine
AbbVie's Humira Still a Growth Engine Motley Fool
View ArticleExperimental J&J psoriasis drug shows promise in study
Experimental J&J psoriasis drug shows promise in study Yahoo/Reuters
View ArticlePfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib...
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis...
View ArticleNovartis' Phase III Results on Secukinumab Published
Novartis' Phase III Results on Secukinumab Published Yahoo/Zacks.com
View ArticleCellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial Yahoo
View Article
More Pages to Explore .....